skip to main content

Severe COPD with chronic bronchitis and frequent exacerbations despite triple inhaled therapy — SCE Respirator

Instant feedback + full explanation. One question, done properly.

HardCOPD GuidelinesSevere COPD with chronic bronchitis and frequent exacerbations despite triple inhaled therapySCE Respiratory

A 66-year-old man with COPD is reviewed in a specialist clinic because of recurrent exacerbations. He reports cough and sputum production on most days and has post-bronchodilator FEV₁ 41% predicted. During the preceding 12 months, he has required two community-treated courses of oral corticosteroids and antibiotics and one hospital admission for a COPD exacerbation. He has used single-inhaler LAMA/LABA/ICS triple therapy for 14 months with good adherence and technique. Vaccination, pulmonary rehabilitation, airway-clearance training and a self-management plan have been completed. CT shows emphysema without bronchiectasis or another pulmonary pathology. Routine and mycobacterial sputum cultures are negative. Stable blood eosinophil counts are 60–90 cells/µL. He continues to smoke five cigarettes daily despite receiving cessation treatment. ECG shows a QTc of 492 ms. BMI is 25.6 kg/m², liver function is normal, and there is no history of psychiatric illness or suicidal ideation. Which additional pharmacological strategy is most appropriate?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Start roflumilast 250 micrograms once daily for 28 days, then increase to 500 micrograms once daily

This patient has the specific NICE phenotype for specialist-initiated roflumilast: severe airflow obstruction defined by post-bronchodilator FEV₁ below 50% predicted, chronic bronchitis and at least two exacerbations in the previous 12 months despite LAMA/LABA/ICS triple therapy. He has no identified contraindication: liver function is normal, weight is satisfactory and there is no relevant psychiatric history. The current SmPC recommends 250 micrograms daily for 28 days to improve initial tolerability, followed by the therapeutic maintenance dose of 500 micrograms daily. Azithromycin is an attractive exacerbation-prevention option because he produces sputum and has had frequent and hospital-treated exacerbations. However, NICE recommends considering it in people who do not smoke and requires exclusion of a prolonged QT interval; this patient fails both discriminators. Theophylline is less effective and less well tolerated than inhaled long-acting bronchodilators and is generally reserved for patients unable to use inhaled therapy or still symptomatic after inhaled bronchodilator trials; it is not the preferred phenotype-directed add-on here. Maintenance oral corticosteroids should normally be avoided in stable COPD because of systemic toxicity. Carbocisteine can be trialled for chronic productive cough and continued if symptoms improve, but it does not supersede the directly applicable NICE recommendation for roflumilast in this frequent-exacerbator chronic-bronchitis phenotype.

Reference: Roflumilast for treating chronic obstructive pulmonary disease: Recommendations (26 July 2017) — https://www.nice.org.uk/guidance/ta461/chapter/1-Recommendations Chronic obstructive pulmonary disease in over 16s: diagnosis and management — Recommendations (Published 5 December 2018; last updated 26 July 2019) — https://www.nice.org.uk/guidance/ng115/chapter/Recommendations Roflumilast 500 micrograms Tablets — Summary of Product Characteristics (Text revised 24 June 2026; updated on emc 29 June 2026) — https://www.medicines.org.uk/emc/product/13453/smpc